Sichuan Kelun-Biotech Biopharmaceutical revenue and financials
$468.60Change from previous close: −1.97%Absolute change: −$9.40
In the fiscal year ended December 2025, Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.06B (+6.46% year over year). The net loss was ¥381.97M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.46%
- 2025 vs 2024
- Net margin
- -18.6%
- 2024: -13.8%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 5,989 | 4,268 | 3,510 | 993 | — |
| Current assets | 5,149 | 3,493 | 2,807 | 332 | — |
| Cash and equivalents | 3,331 | 1,343 | 1,569 | 119 | — |
| Short-term investments | 1,228 | 1,732 | 960 | — | — |
| Inventory | 241 | 111 | 63.0 | 52.6 | — |
| Net property, plant and equipment | 723 | 721 | 655 | 609 | — |
| Other intangible assets | 37.1 | 39.4 | 39.1 | 41.8 | — |
| Current liabilities | 1,004 | 810 | 1,110 | 4,167 | — |
| Accounts payable | 409 | 282 | 383 | 151 | — |
| Total debt | 88.4 | 127 | 59.9 | 3,014 | — |
| Total liabilities | 1,121 | 959 | 1,180 | 4,219 | — |
| Total equity (incl. minority) | 4,867 | 3,309 | 2,329 | -3,226 | — |
| Retained earnings | -4,705 | -4,323 | -4,056 | -3,482 | — |